---
title: "Veterinary 13Fs: Idexx, Zoetis, Elanco, Covetrus Decoded"
type: learn
slug: veterinary-13f-idxx-zts-decoder
canonical_url: https://13finsight.com/learn/veterinary-13f-idxx-zts-decoder
published_at: 2026-05-16T17:27:45.954Z
updated_at: 2026-05-16T17:27:49.042Z
author: Sarah Mitchell
author_title: Education Editor
author_url: https://13finsight.com/authors/sarah-mitchell
word_count: 657
locale: en
source: 13F Insight
---

# Veterinary 13Fs: Idexx, Zoetis, Elanco, Covetrus Decoded

> Idexx Laboratories, Zoetis, Elanco Animal Health, plus Covetrus (taken private 2022) and Phibro Animal Health anchor US-traded veterinary 13F positioning. Multi-year emerging pet humanization, companion animal health spending, plus emerging emerging GLP-1 for pets drive distinctive institutional patterns.

US-traded veterinary equities form a distinctive specialty healthcare corner of institutional 13F positioning. Idexx Laboratories (IDXX, dominant pet diagnostics), Zoetis (ZTS, largest pet pharma plus livestock), Elanco Animal Health (ELAN, pet plus livestock pharma post-Bayer Animal Health acquisition), plus Covetrus (taken private by Clayton Dubilier & Rice and TPG 2022) and Phibro Animal Health (PAHC) anchor the cohort. Multi-year emerging pet humanization, companion animal health spending, plus emerging emerging GLP-1 for pets drive distinctive institutional positioning. Reading veterinary 13F positioning requires understanding the companion-vs-livestock framework plus the multi-year dynamics.The veterinary business modelVeterinary companies operate four primary economic engines:Companion animal economics. Multi-year emerging companion animal economics drives operator revenue. Multi-year emerging US pet ownership 65% of households plus emerging emerging emerging emerging 90M+ dogs plus 95M+ cats plus emerging emerging emerging emerging pet humanization plus emerging emerging emerging emerging premium pet products drive multi-year emerging operator economics. Multi-year emerging emerging US veterinary spending exceeded $35B (2024) plus emerging emerging multi-year ramp to $50B+ by 2030.Pet diagnostics dynamics. Multi-year emerging pet diagnostics dynamics drives Idexx operator economics. Multi-year emerging Idexx VetLab (in-clinic diagnostics) plus emerging emerging Idexx Reference Laboratories (mail-in samples) plus emerging emerging Idexx Rapid Assay Tests plus emerging emerging Idexx LivestockPoultry plus emerging emerging Idexx Water plus emerging emerging emerging emerging Idexx 360 software drive multi-year emerging emerging recurring revenue. Multi-year emerging emerging Idexx CAG (Companion Animal Group) 90%+ revenue mix.Pet pharma plus emerging GLP-1 for pets. Multi-year emerging pet pharma plus emerging GLP-1 for pets drives multi-year emerging operator strategic positioning. Multi-year emerging Zoetis Apoquel (dermatology) plus emerging emerging Cytopoint plus emerging emerging Librela (canine osteoarthritis monoclonal antibody) plus emerging emerging Solensia (feline osteoarthritis) plus emerging emerging Simparica (parasiticides) drive multi-year emerging companion animal pharma growth. Multi-year emerging emerging Zoetis GLP-1 for pets emerging emerging emerging clinical development potential.Livestock animal health emerging. Multi-year emerging livestock animal health drives Elanco plus emerging emerging Zoetis Livestock operator economics. Multi-year emerging cattle plus emerging emerging poultry plus emerging emerging swine plus emerging emerging aquaculture animal health drive multi-year emerging operator economics. Multi-year emerging emerging Elanco bovine plus emerging emerging poultry plus emerging emerging companion animal divisions plus emerging emerging emerging cattle methane reduction (Bovaer) drive multi-year emerging operational trajectory.Major US-traded veterinary namesIdexx Laboratories (IDXX)Dominant pet diagnostics plus emerging emerging Companion Animal Group plus emerging emerging Livestock-Poultry-Dairy plus emerging emerging Water plus emerging emerging Other plus emerging emerging Jay Mazelsky CEO leadership.Zoetis (ZTS)Largest pet pharma plus emerging emerging post-Pfizer Animal Health spinoff (2013) plus emerging emerging companion animal plus emerging emerging livestock plus emerging emerging diagnostics (Vetscan) plus emerging emerging Kristin Peck CEO leadership.Elanco Animal Health (ELAN)Diversified pet plus emerging emerging livestock pharma plus emerging emerging post-Bayer Animal Health acquisition (2020 at $7.6B) plus emerging emerging Pet Health plus emerging emerging Farm Animal plus emerging emerging Jeff Simmons CEO leadership.Covetrus (taken private)Diversified veterinary distribution plus emerging emerging software (Cornerstone, Pulse) plus emerging emerging taken private by Clayton Dubilier & Rice and TPG 2022 at $4B plus emerging emerging Ben Wolin CEO leadership.Phibro Animal Health (PAHC)Diversified livestock animal health plus emerging emerging Performance Products plus emerging emerging Mineral Nutrition plus emerging emerging Vaccines plus emerging emerging Jack Bendheim CEO leadership.How institutional managers position around veterinaryThree patterns appear across smart-money 13Fs:Pattern 1: Quality-leadership concentrationIDXX, ZTS-concentrated growth manager positions reflect quality companion animal leadership plus emerging emerging pet humanization thesis.Pattern 2: Turnaround positioningELAN-concentrated value-discipline manager positions reflect Elanco turnaround plus emerging emerging Bayer Animal Health integration thesis.Pattern 3: Specialty positioningPAHC-concentrated active manager positions reflect livestock specialty thesis.How to read veterinary 13F positioningThree rules apply:Rule 1: Identify segment exposureCompanion vs livestock vs diagnostics have distinct dynamics.Rule 2: Watch organic revenue growthMulti-year organic revenue drives operator economics.Rule 3: Cross-check pet humanizationMulti-year pet humanization drives companion spending.What veterinary positioning signalsQuality-leadership conviction. Concentrated IDXX, ZTS positions signal quality leadership thesis.Turnaround conviction. Concentrated ELAN positions signal Elanco turnaround thesis.Specialty conviction. Concentrated PAHC positions signal livestock specialty thesis.For real-time tracking of veterinary 13F activity, see the institutional signals feed.

## FAQ

### What are the major US-traded veterinary companies?

Five major US-traded veterinary: (1) Idexx Laboratories (IDXX) — dominant pet diagnostics; (2) Zoetis (ZTS) — largest pet pharma plus livestock; (3) Elanco Animal Health (ELAN) — pet plus livestock pharma post-Bayer Animal Health acquisition; (4) Covetrus (taken private by Clayton Dubilier & Rice and TPG 2022) — veterinary distribution; (5) Phibro Animal Health (PAHC) — livestock animal health.

### How does companion animal economics work?

Companion animal economics drives operator revenue. US pet ownership 65% of households plus 90M+ dogs plus 95M+ cats plus pet humanization plus premium pet products drive operator economics. US veterinary spending exceeded $35B (2024) plus multi-year ramp to $50B+ by 2030. Multi-year emerging veterinary visits plus emerging dental cleanings plus diagnostics plus emerging emerging veterinary surgery drive multi-year emerging operator economics.

### How does pet diagnostics dynamics work?

Pet diagnostics dynamics drives Idexx operator economics. Idexx VetLab (in-clinic diagnostics) plus Idexx Reference Laboratories (mail-in samples) plus Idexx Rapid Assay Tests plus Idexx LivestockPoultry plus Idexx Water plus Idexx 360 software drive recurring revenue. Idexx Companion Animal Group (CAG) 90%+ revenue mix. Multi-year emerging IDXX placement (instruments installed at vet clinics) drives multi-year recurring consumables revenue.

### What is Zoetis's Librela?

Zoetis Librela (bedinvetmab, canine osteoarthritis monoclonal antibody) drives multi-year emerging pet pharma growth. FDA-approved May 2023 plus emerging emerging European launch 2024 plus emerging emerging US launch 2025. Multi-year emerging Librela first monoclonal antibody for canine osteoarthritis pain plus emerging emerging multi-year ramp potential ($300M-1B+ peak revenue) plus emerging emerging FDA adverse event monitoring drive multi-year operational trajectory.

### How does GLP-1 for pets emerge?

GLP-1 for pets dynamics drives operator strategic positioning. Zoetis plus emerging Elanco plus emerging emerging Big Pharma (Eli Lilly emerging emerging Novo Nordisk) clinical development potential for canine plus feline obesity GLP-1 analogs. Multi-year US 60%+ dog obesity plus 60%+ cat obesity drive multi-year potential demand. Multi-year emerging GLP-1 for pets clinical development plus FDA approval plus commercial launch 2027-2030 emerging emerging timeline.

### What signals veterinary cycle inflections?

Four signals: (1) organic revenue growth plus emerging companion animal dynamics; (2) Librela plus Solensia plus emerging pet pharma adoption; (3) Idexx placement plus emerging emerging consumables growth; (4) M&A activity plus emerging GLP-1 for pets emerging emerging development. Concentrated 13F changes around these signals reveal manager cycle reading.

---

Source: 13F Insight — https://13finsight.com/learn/veterinary-13f-idxx-zts-decoder
Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell
Last updated: 2026-05-16T17:27:49.042Z